RARE
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) has 11 SEC Form 4 filings (12 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Jul 6, 2026.
Insiders have net sold $522K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Emil D. Kakkis
- Employees:1,294
- HQ:Novato, CA, US
- IPO:2014-01-31
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$522K
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$3.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Financial Officer | Sale | 4,698 | $156K | Jul 6 | SEC ↗ | |
| Director | Sale | 2,000 | $50K | Jun 15 | SEC ↗ | |
Parschauer Karah HerdmanFirst filing | EVP and Chief Legal Officer | Sale | 1,899 | $47K | Jun 15 | SEC ↗ |
SULIMAN SHEHNAAZFirst filing | Director | Sale | 5,740 | $144K | May 18 | SEC ↗ |
Crombez EricFirst filing | EVP and Chief Medical Officer | Sale | 344 | $9K | May 6 | SEC ↗ |
Horn HowardFirst filing | Chief Financial Officer | Sale | 4,683 | $117K | May 4 | SEC ↗ |
Related companies
Ultragenyx Pharmaceutical Inc. is in the Healthcare sector.